等待開盤 08-14 09:30:00 美东时间
+2.560
+63.21%
Generation Bio (NASDAQ:GBIO) reported quarterly losses of $(3.12) per share which missed the analyst consensus estimate of $(2.62) by 19.08 percent. This is a 906.45 percent decrease over losses of $(0.31) per share from
08-13 05:38
Generation Bio shares are trading higher after the company announced new data d...
08-13 04:25
Generation Bio announced new data demonstrating their cell-targeted lipid nanoparticle (ctLNP) system successfully delivered siRNA to T cells in non-human primates, a first in the field. The system showed potent and selective knockdown of beta-2 microglobulin, LAT1, and VAV1, potentially addressing T cell-driven autoimmune diseases. The company reported a cash balance of $141.4 million as of June 30, 2025, and is evaluating strategic alternatives...
08-12 20:05
Generation Bio shares are trading higher after the company announced it has bee...
07-26 02:44
Generation Bio shares are trading lower after the company announced a 1-for-10 ...
07-18 22:51
Generation Bio announced a 1-for-10 reverse stock split to increase its share price and regain compliance with Nasdaq listing requirements. Effective July 21, 2025, every 10 shares will be combined into 1 share, reducing outstanding shares from ~67.3M to ~6.7M. The stock will resume trading on July 22 under the same symbol "GBIO" with a new CUSIP. Adjustments will be made to equity plans, and fractional shares will be paid in cash. The goal is to...
07-18 12:35
Generation Bio Co. granted 128,600 non-statutory stock options to a new employee on July 1, 2025, under its 2025 Inducement Stock Incentive Plan. The options have an exercise price of $0.32 per share, a 10-year term, and vest over four years, with 25% vesting on the first anniversary and 6.25% quarterly thereafter. The company specializes in treating T cell-driven autoimmune diseases by reprogramming T cells to reduce autoreactive cells using lip...
07-07 20:05
Generation Bio Co. (Nasdaq:GBIO) announced that its CEO, Geoff McDonough, M.D., will present at the Jefferies Global Healthcare Conference on June 4th. The presentation will focus on the company's work to treat T cell-driven autoimmune diseases by reprogramming T cells using lipid nanoparticles (ctLNP) to deliver siRNA, targeting disease-driving genes. A live webcast and replay will be available on the company's investor website. --- Generation...
05-28 10:59
Gainers Shuttle Pharmaceuticals (NASDAQ:SHPH) stock increased by 79.5% to $0.4...
05-09 20:10
Across the recent three months, 4 analysts have shared their insights on Genera...
05-09 06:01